See the original post:
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a...

Read the original:
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

See the original post:
VYRA™ Product Line Update

See the original post here:
ProKidney to present at upcoming investor conferences

Here is the original post:
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

Read more here:
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

More here:
T2 Biosystems Announces Issuance of U.S. Patent for Direct Detection of Lyme Disease

Read more:
TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference

See the original post here:
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th...

View original post here:
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

The rest is here:
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal

More:
Vaccitech to Present at the H.C. Wainwright Global Investment Conference

The rest is here:
Growcentia, a leading provider of scientifically driven biological solutions for agriculture and horticulture, celebrates grand opening of new...

Originally posted here:
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

The rest is here:
Biomea Fusion to Attend H.C. Wainwright Global Investment Conference

See the rest here:
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022

Read the original here:
Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT

Go here to read the rest:
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Here is the original post:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Continue reading here:
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension